Compare BTG & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | LEGN |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 2007 | 2020 |
| Metric | BTG | LEGN |
|---|---|---|
| Price | $5.87 | $21.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | $6.00 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 24.0M | 2.6M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.08 | $42.68 |
| Revenue Next Year | $28.46 | $30.52 |
| P/E Ratio | $34.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.57 | $16.24 |
| 52 Week High | $6.29 | $37.50 |
| Indicator | BTG | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 74.43 | 47.78 |
| Support Level | $4.82 | $20.70 |
| Resistance Level | $5.77 | $21.97 |
| Average True Range (ATR) | 0.20 | 1.08 |
| MACD | 0.08 | 0.40 |
| Stochastic Oscillator | 95.09 | 56.09 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.